Digistain GTM brain

Digistain sells a breast cancer recurrence-risk test to clinical teams treating eligible early-stage patients.

category

Breast cancer prognostic diagnostics

market profile

  • text: A professional-use prognostic test competes with RNA-based tumour profiling for information used in early breast cancer care.
  • text: Clinical validation, local regulatory status and payer acceptance are material adoption factors for a new diagnostic.

personas

  • title: Breast medical oncologist
    pains:
    • Needs recurrence-risk information for multidisciplinary treatment discussions
    • Long turnaround times can delay a discussion with an anxious patient
  • title: Histopathology laboratory lead
    pains:
    • Wants a test that fits routine tissue handling
    • Must assess specimen logistics, evidence and turnaround alongside existing assays
  • title: Cancer service procurement or clinical director
    pains:
    • Must balance diagnostic access against test budgets
    • Needs evidence and implementation details before changing the clinical pathway

icp

  • text: Breast cancer centres and hospital oncology teams treating stage I-II, ER-positive, HER2-negative invasive disease with up to three positive nodes.
  • text: UK hospitals with established histopathology and multidisciplinary breast cancer pathways are a natural initial fit; market access must be assessed by jurisdiction.

message pillars

  • text: Results are intended to arrive quickly after the laboratory receives a specimen.
  • text: The test uses routine tissue rather than molecular extraction.
  • text: The output supports the clinical team rather than replacing judgment.

objections

  • objection: Is the score sufficient to choose chemotherapy?
    response: The company describes the result as probabilistic information for multidisciplinary discussion alongside established factors and clinical judgment.
  • objection: Will this disrupt the pathology workflow?
    response: The test uses routine FFPE sections; confirm sample shipment and local operational requirements with Digistain.
  • objection: How does evidence compare with established genomic assays?
    response: Review the published validation, local guidance and reimbursement with the clinical team before adoption.

competitors

  • name: Exact Sciences
    why: Oncotype DX is an established breast cancer recurrence assay.
  • name: Agendia
    why: MammaPrint provides genomic risk profiling in early breast cancer.
  • name: OncoStem Diagnostics
    why: CanAssist Breast addresses risk assessment and treatment decisions in early breast cancer.

influencers

  • name: Hemmel Amrania
    url: https://digistain.co.uk/the-team/
    why: Founder and scientific lead with direct expertise in the test.
  • name: Chris Phillips
    url: https://www.imperial.ac.uk/news/240611/rapid-breast-cancer-screening-technology-could/
    why: Scientific co-founder and Imperial researcher.

keywords

  • breast cancer recurrence risk test
  • ER positive HER2 negative prognostic test
  • breast tumour profiling
  • Oncotype DX alternative
  • early breast cancer risk stratification
  • histopathology prognostic score

voice

  • Clinical and evidence-led
  • Measured about physician judgment
  • Focused on speed and access

signals

  • text: A breast MDT reviews turnaround times or access to recurrence-risk testing for eligible patients.
  • text: A cancer centre is assessing the budget or workflow for tumour profiling assays.

pricing

model: unknown

motion

sales_led

channels

  • clinical publications
  • medical conferences
  • clinician education
  • LinkedIn

confidence

medium

Founders

  • name: Hemmel Amrania
    title: Founder
    role: Founder
    bio: Hemmel Amrania Ph.D, CEO has previously scaled several 7 figure businesses both in therapeutics and diagnostics. As a doctoral researcher he was awarded the Outstanding Research Prize at Imperial College London. He has also won several UK business awards including the Innovation & Entrepreneurship Challenge Imperial College and the Climate KIC Competition held by the Mayor of London. For Digistain he spear-headed the research out of the lab all the way through to clinical trials.
  • name: Chris Phillips
    title: Founder
    role: Founder
    bio: Chris is an Imperial College Physics Professor, researching into photovoltaics, and biomedical imaging. He's spent the last few years, with Hemmel Amrania, developing the Digistain cancer diagnosis technology with Imperial medics. He has won a number of prizes and has explained his research on invisibility caused by quantum optical effects to comedy legend Cleese on TV. He once rowed 500 miles non-stop from London to Paris. See https://en.wikipedia.org/wiki/Chris_Phillips_(professor)

Back to YC companies